Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06673056 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 11 of 11 sites
    v5
  2. Site details revised at 9 of 11 sitesv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 9 to 11
    • Start date changed from estimate of Mar 1, 2025 to Mar 18, 2025
    v3
  4. Study sites: 8 to 9
    • Secondary endpoints: 4 to 5
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Ataxia-Telangiectasia (A-T). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.
Trial Details
NCT Number NCT06673056
Lead Sponsor IntraBio Inc
Conditions
(from sponsor)		 Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
Related terms Ataxia Telangiectasia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov